Pulmonary Fibrosis
6 drugs928 FAERS reportsMedDRA PT
GET
/api/v1/reaction/pulmonary-fibrosisReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D011658
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Source: U.S. National Library of Medicine — MeSH (Pulmonary Fibrosis)
Drugs reporting Pulmonary Fibrosis (6)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Triprolidine10538%
- 2Pyrilamine4912%
- 3Glucagon1714.2%
- 4Amiodarone3933.6%
- 5Elbasvir1052.5%
- 6Grazoprevir1052.5%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Pulmonary Fibrosis as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Nutritional Composition and Potential Actions of Bioactive Compounds From Wild Laurus nobilis in the Management of Pulmonary Fibrosis-Induced Cardiopathy in Rats.Molecular nutrition & food research · 2026 · Jedidi S, Ayari A, Abidi A, et al.PMID 42206476DOI 10.1002/mnfr.70504
- Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework.Frontiers in immunology · 2026 · Zhang W, Yi J, Li Z, et al.PMID 42206055DOI 10.3389/fimmu.2026.1847027
- Correction: Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework.Frontiers in immunology · 2026 · Zhang W, Yi J, Li Z, et al.PMID 42206046DOI 10.3389/fimmu.2026.1874174
- Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry.Lung · 2026 · Shetty S, Swaminathan AC, Li P, et al.PMID 42201372DOI 10.1007/s00408-026-00895-x
- Antifibrotic Drugs Regulate the Expression of Epithelial Sodium Channels in the Lungs.Advances in respiratory medicine · 2026 · Ito T, Fujimoto H, Toda M, et al.PMID 42201233DOI 10.3390/arm94030030
- Integrated Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulations Accelerate the Discovery of Novel PDE1 Inhibitors with Potential for the Treatment of Idiopathic Pulmonary Fibrosis.Molecules (Basel, Switzerland) · 2026 · Cai XL, Xue ZH, He SJ, et al.PMID 42197287DOI 10.3390/molecules31101731
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.